8-K

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) January 10, 2005

                               IMMUNOMEDICS, INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)

          Delaware                     000-12104                61-1009366
- ----------------------------        -------------           ------------------
(State or other jurisdiction          (Commission            (I.R.S. Employer
      of incorporation)              File Number)           Identification No.)

     300 American Road, Morris Plains, New Jersey                 07950
     --------------------------------------------               ---------
      (Address of principal executive offices)                  (Zip Code)

Registrant's telephone number, including area code  (973) 605-8200

                                 Not Applicable
         --------------------------------------------------------------
         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities Act
     (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
     (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

================================================================================



ITEM 5.02  DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF
           DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.

           (d) On January 11, 2005, Immunomedics, Inc. (the "Company") issued a
press release announcing that Don C. Stark has been appointed to the Company's
Board of Directors on January 10, 2005. It has not yet been determined on which
committees of the Board of Directors Mr. Stark will serve. A copy of the press
release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.

ITEM 9.01  FINANCIAL STATEMENTS AND EXHIBITS.

           (c) Exhibits:

                   99.1  Press Release, dated January 11, 2005



                                   SIGNATURES

           Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                             IMMUNOMEDICS, INC
                                             -----------------------------------
                                             (Registrant)

Date January 12, 2005
                                             By:     /s/ GERARD G. GORMAN
                                                     ---------------------------
                                             Name:   Gerard G. Gorman
                                             Title:  Vice President, Finance and
                                                     Chief Financial Officer

EX-99.1

                                                                    Exhibit 99.1

                COURTESY OF PR NEWSWIRE COMPLIMENTARY MONITORING

             IMMUNOMEDICS ELECTS DON C. STARK TO BOARD OF DIRECTORS

PR Newswire -- January 11, 2005

MORRIS PLAINS, N.J., Jan. 11 /PRNewswire-FirstCall/ -- Immunomedics, Inc.
(Nasdaq: IMMU) today announced that Mr. Don C. Stark has been appointed to the
Company's Board of Directors. Mr. Stark is the Chief Executive Officer and
President of Whistler Associates, a marketing and strategic planning consulting
firm for companies focused on oncology. Prior to founding Whistler Associates,
Inc., in 1996, Mr. Stark held various market research, marketing and business
development positions at Bristol-Myers Oncology Division, Immunex, and Repligen,
all in the fields of oncology and immunology. Mr. Stark is also a founder and
member of the Board of Directors of Strategic Answers Inc., a forecasting and
information service provider to the pharmaceutical industry.

Mr. Stark stated: "I am excited about the prospects for Immunomedics. Although
the Company has long been known for its inroads in the treatment of cancer with
four therapeutic candidates currently in the clinic, Immunomedics has recently
achieved a milestone in the treatment of autoimmune disease with the FDA's award
of fast track designation of epratuzumab for lupus therapy. The Company also has
a very robust product pipeline of novel agents in various stages of development.
I look forward to working closely with the Company in pursuit of its growth
strategy."

Dr. David M. Goldenberg, Chairman of the Board and founder of the Company,
remarked: "We are delighted to have such an experienced and capable
pharmaceutical marketing executive as Don join us. His commercial development
experience in the fields of oncology and immunology are of particular value to
us as we advance our therapeutic product candidates and seek partnering
opportunities for their commercialization."

Immunomedics is a biopharmaceutical company focused on the development of
monoclonal, antibody-based products for the targeted treatment of cancer,
autoimmune and other serious diseases. We have developed a number of advanced
proprietary technologies that allow us to create humanized antibodies that can
be used either alone in unlabeled or "naked" form, or conjugated with
radioactive isotopes, chemotherapeutics or toxins, in each case to create highly
targeted agents. Using these technologies, we have built a pipeline of
therapeutic product candidates that utilize several different mechanisms of
action. We believe that our portfolio of intellectual property, which includes
approximately 90 issued patents in the United States, and more than 250 other
issued patents worldwide, protects our product candidates and technologies.



This release, in addition to historical information, contains forward- looking
statements made pursuant to the Private Securities Litigation Reform Act of
1995. Such statements, including statements regarding clinical trials,
out-licensing arrangements, and capital raising activities, involve significant
risks and uncertainties and actual results could differ materially from those
expressed or implied herein. Factors that could cause such differences include,
but are not limited to, risks associated with new product development (including
clinical trials outcome and regulatory requirements/actions), competitive risks
to marketed products and availability of financing and other sources of capital,
as well as the risks discussed in the Company's Annual Report on Form 10-K for
the fiscal year ended June 30, 2004. The Company is not under any obligation,
and the Company expressly disclaims any obligation, to update or alter any
forward-looking statements, whether as a result of new information, future
events or otherwise.

Company Contact: Chau Cheng, Associate Director, Investor Relations & Business
Analysis, (973) 605-8200, extension 123. Visit the Company's web site at
http://www.immunomedics.com.

SOURCE  Immunomedics, Inc.
     -0-                             01/11/2005
     /CONTACT:  Chau Cheng, Associate Director, Investor Relations & Business
Analysis of Immunomedics, Inc., +1-973-605-8200, ext. 123
     /Web site:  http://www.Immunomedics.com